This activity is supported by an educational grant from Novo Nordisk.
NPs and PAs
Describe the mechanism of action of GLP-1 RAs as it relates the pathophysiology and progression of T2D
Differentiate among the GLP-1 RAs based on dosing, administration, and glycemic and extraglycemic effects
Apply guideline recommendations, cardiovascular and/or renal risk factors, and patient preferences to select GLP-1 RAs for appropriate patients early in the treatment of T2D
Incorporate strategies to manage the adverse events associated with GLP-1 RAs to promote adherence
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Debbie Hinnen, APN, BC-ADM, CDCES: consultant/advisor/speaker: Intuity, Lilly/Boehringer Ingelheim, Novo Nordisk, Sanofi.
Lucia M. Novak, MSN, ANP-BC, BC-ADM: consultant/advisor/speaker: Abbott Diabetes Care, BI/Lilly, Novo Nordisk, Prevention Bio, Xeris.
Daniel Thibodeau, DHSc, MHP, PA-C: consultant/advisor/speaker: Arbor Pharmaceuticals.
Susan Tiso, DNP, FNP-BC has no relevant financial relationships to disclose.
None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose, except Lucia M. Novak, MSN, ANP-BC, BC-ADM and Daniel Thibodeau, DHSc, MHP, PA-C, as noted above.
Participants wishing to earn CE/CME credit must:
The estimated time to complete this activity is 1.00 hour.
Release date: September 15, 2022
Expiration date: September 14, 2023
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Lucia M. Novak, MSN, ANP-BC, BC-ADM, Diabetes Consulting Services, North Bethesda, Maryland
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until September 14, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Daniel Thibodeau, DHSc, MHP, PA-C, Eastern Virginia Medical School, Norfolk, Virginia
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credits for learning and change.
This program has been made available online.